MBX - CIK 0001776111
The table below shows MBX Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Operating cash flow | -$20.21M | -$22.68M | -$10.71M |
| Capital expenditure | $437.00K | $30.00K | $273.00K |
| Investing cash flow | -$97.10M | $3.23M | $15.43M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $87.44M | $4.00K | $183.00K |
MBX Biosciences, Inc. reported operating cash flow of -$79.95M for fiscal year 2025. That is down 46.2% from -$54.68M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.